Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:20:23.389Z.
Consensus retrieved: 2026-10-06T08:16:35.409Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:20:23.389Z.
Quote observation: 2026-10-06T14:20:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 06927155e4c2426002f4bce692deae0e66dfd07f15f24b5879cea6ac7a363957
Forward PE Ratio (N/A) = Dated Quote Price ($13.21) / Consensus Forward EPS ($-0.66)
FORWARD PE RATIO
N/A
AbCellera Biologics Inc.
Market Cap
$4.04B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.04B | N/A |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | N/A |
| LivaNova PLC (LIVN)vs › | $4.15B | 17.33 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.26B | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.39B | 8.33 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.43B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.63B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $13.21, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.67 | $-0.70 – $-0.63 | 6 | n/m |
| 2027-12-31 | $-0.74 | $-0.77 – $-0.65 | 5 | n/m |
| 2028-12-31 | $-0.84 | $-0.92 – $-0.66 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
